What are suitable add-on medications for post-traumatic stress disorder (PTSD) in patients already taking Venlafaxine (Effexor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2025 • View editorial policy

From the Guidelines

Suitable Add-on Medications for PTSD

For patients with PTSD who are already on venlafaxine, a potential add-on medication could be a second-generation antipsychotic such as risperidone, starting at a low dose of 0.5-1mg at bedtime, or an alpha-1 adrenergic receptor blocker like prazosin, starting at 1-2mg at bedtime 1, 2, 3. Alternatively, an augmenting agent like topiramate, starting at 25mg at bedtime and gradually increasing to 50-100mg, could be considered.

  • Key considerations for these medications include their potential to reduce nightmare frequency and improve sleep quality, as evidenced by studies on risperidone's efficacy in treating PTSD-related nightmares 3.
  • Risperidone has shown moderate to high efficacy in two studies, with doses ranging from 0.5-3 mg per day, and has been associated with a significant decrease in nightmare frequency 3.
  • Prazosin and topiramate are also mentioned as potential options for treating PTSD-associated nightmares, although the evidence for their use is less clear 1, 2. However, it's crucial to carefully weigh the potential benefits against the risks and monitor the patient closely for any adverse effects or interactions.
  • Monitoring for side effects, such as those associated with atypical antipsychotics or alpha-1 adrenergic receptor blockers, is essential to ensure safe and effective treatment.
  • Individualized treatment plans should be developed based on the patient's specific needs and circumstances, taking into account the available evidence and clinical judgment 1, 2.

From the Research

Suitable Add-on Medications for PTSD

In patients already taking Venlafaxine (Effexor) for post-traumatic stress disorder (PTSD), several medications can be considered as add-on therapies. The following options are supported by existing research:

  • Prazosin: This medication has shown small statistically significant evidence for reducing PTSD symptoms when used as an augmentation therapy 4.
  • Risperidone: Similar to prazosin, risperidone has demonstrated a small positive effect when used to augment pharmacological monotherapy for PTSD 4.
  • Quetiapine: As a second-generation antipsychotic, quetiapine has been found to be effective in reducing PTSD symptoms, including re-experiencing, avoidance, and hyperarousal symptoms, as well as depressive and anxiety symptoms 5, 6. It is often prescribed for its sedative effects, which can be beneficial for patients with PTSD 5.

Considerations for Add-on Medications

When selecting an add-on medication for PTSD, it is essential to consider the individual patient's clinical features and comorbidities. For example:

  • Patients with psychotic depression may benefit from the use of quetiapine, which has been shown to be effective in treating this condition 7.
  • Patients with high levels of disability may require combined treatment with evidence-based psychotherapy, as this has been found to predict meaningful improvement in PTSD symptoms 8.

Available Research

The existing research on add-on medications for PTSD is primarily based on studies of monotherapy and augmentation strategies. While some medications, such as quetiapine, have shown promise in reducing PTSD symptoms, more research is needed to fully understand their efficacy and safety in this context 6.

References

Guideline

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Guideline

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Guideline

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Research

Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.